Company profile
RHYTHM PHARMACEUTICALS, INC.
NASDAQ:RYTMBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IMCIVREE | approved | $71.3MQ2 2026 | 0 | — |
| SETMELANOTIDE | phase4 | — | 22 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (25)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07156578 | phase2 | enrolling_by_invitation | 2025-11-10 | 2028-04-15 | Rhythm Pharmaceuticals, Inc. | A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) |
| NCT04348175 | phase1 | completed | 2020-07-09 | 2021-04-17 | Rhythm Pharmaceuticals, Inc. | A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Impairment |
| NCT06239116 | phase1_2 | active_not_recruiting | 2024-03-05 | 2027-05-07 | Rhythm Pharmaceuticals, Inc. | A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment |
| NCT06772597 | phase2 | active_not_recruiting | 2025-03-04 | 2026-10-31 | Rhythm Pharmaceuticals, Inc. | A Study of Setmelanotide in Patients With Prader-Willi Syndrome |
| NCT06046443 | phase2 | completed | 2024-07-11 | 2026-02-09 | Rhythm Pharmaceuticals, Inc. | A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 213793 | 2020-11-25 | NDA | RHYTHM PHARMACEUTICALS INC | |||||
Loading… | ||||||||